Loading clinical trials...
Loading clinical trials...
The study will evaluate the efficacy and safety of gevokizumab in treating active ulcers of pyoderma gangrenosum (PG).
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
XOMA (US) LLC
NCT06624670 · Pyoderma Gangrenosum
NCT07444684 · Pyoderma Gangrenosum
NCT05964413 · Pyoderma Gangrenosum
NCT04901325 · Pyoderma Gangrenosum, Skin Diseases, and more
NCT04792957 · Pyoderma Gangrenosum, Hidradenitis Suppurativa, and more
Coral Gables, Florida
North Miami Beach, Florida
Ann Arbor, Michigan
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions